Any current/future capex/capital investment/strategic investment?

Medanta plans to increase bed capacity from ~2,700 to ~4,000 beds over the next three years. Total expected capex of approximately INR 1,000 crores for adding around 1,200-1,300 beds between FY24 and FY26. INR 450 crores capex expected in the current year (FY24), including around INR 250 crores for the Noida Hospital project. Noida facility: 550-bed hospital, expected to open in late FY25, operationalizing about 300 beds initially and scaling up as needed. Gurgaon facility undergoing expansion with about 80 new senior doctors; adding ~30 beds in mother and child floor and ~50 beds for oncology

Future growth expectations in sales/revenue/volumes?

Continued ramp-up of Patna and Lucknow facilities to full capacity, expected to drive volume and revenue growth. Launch of new 550-bed facility in Noida and 300+ bed hospital project in Indore to expand capacity and market reach. Addition of about 80 senior doctors and new clinical services (e.g., mother and child, lung transplant, chest surgery) at Gurgaon to boost volumes. Focus on increasing operating efficiencies and material/employee cost optimizations to improve margins alongside revenue growth. Tariff increases implemented in early 2023 expected to contribute positively to margi

Future growth expectations in earnings/operating earnings/profits/EPS?

Medanta projects continued deliberate and sustainable growth focusing on ramping up Patna and Lucknow facilities to full capacity. Addition of new clinical talent, including 80 senior doctors mainly in Gurgaon, will drive volume and service expansion. New service lines such as mother and child care, lung transplant, chest surgery, and premium cancer services are expected to boost top line. Recently initiated tariff revisions, especially in Gurgaon, will positively impact revenue and margins going forward. EBITDA margins improved to 24.5% in FY23; management expects margins to stabilize and pot

Global Health LtdQ4 FY23Healthcare Services

Global Health Ltd Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,270.3P/E: 59.6Market Cap: ₹34.2K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Continued ramp-up of Patna and Lucknow facilities to full capacity, expected to drive volume and revenue growth.
Launch of new 550-bed facility in Noida and 300+ bed hospital project in Indore to expand capacity and market reach.
Addition of about 80 senior doctors and new clinical services (e.g., mother and child, lung transplant, chest surgery) at Gurgaon to boost volumes.
Focus on increasing operating efficiencies and material/employee cost optimizations to improve margins alongside revenue growth.
Tariff increases implemented in early 2023 expected to contribute positively to margins and revenue.
Strong inpatient volume growth (32% YoY) and outpatient growth (15.4% YoY) in FY23, with further growth expected as facilities mature.
Expansion into premium cancer and mother-child beds (30 and 50+ beds respectively) to drive higher value service volumes.
Stable and improving margin guidance excluding other income around 20-22%.

Margin guidance

Category 3

Medanta projects continued deliberate and sustainable growth focusing on ramping up Patna and Lucknow facilities to full capacity.
Addition of new clinical talent, including 80 senior doctors mainly in Gurgaon, will drive volume and service expansion.
New service lines such as mother and child care, lung transplant, chest surgery, and premium cancer services are expected to boost top line.
Recently initiated tariff revisions, especially in Gurgaon, will positively impact revenue and margins going forward.
EBITDA margins improved to 24.5% in FY23; management expects margins to stabilize and potentially improve with scaling and better utilization.
New projects include a 550-bed facility in Noida and a 300+ bed hospital in Indore to further increase capacity and revenue streams.
Patna hospital, though still stabilizing, has delivered healthy margins and will contribute more profits as services like radiation oncology start.

See what Global Health Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

- As of March 2023, Medanta became a net debt-free company with a net cash surplus of INR 4,692 million. - INR 500 crore IPO proceeds were utilized largely (INR 375 crore) towards debt repayment completed in April 2023. - No explicit mention of planned new fundraising through debt or equity in the provided transcript. - The company is well capitalized to fund future expansion and growth from its robust balance sheet and strong operating cash flow. - Planned capital expenditure of around INR 1,000 crore over the next three years for capacity expansion is expected to be funded internally. - If needed, specific calls and clarifications on detailed financials can be arranged, but there is no stated intent for immediate fundraising. In summary, currently no announced or planned new fundraising through debt or equity. The company relies on a strong balance sheet and cash flow to fund expansion.

Order book

The transcript and document do not explicitly mention any details about current or expected order book or pending orders for Medanta – Global Health Limited. The content primarily focuses on operational performance, expansion plans, patient volumes, tariff revisions, bed capacity, and financial results. There is no direct reference to order book status or pending orders. If you seek detailed information on contracts, order books, or pending orders, it may require a follow-up with the company directly or checking their official disclosures or investor presentations beyond this transcript.

See what Global Health Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Medanta plans to increase bed capacity from ~2,700 to ~4,000 beds over the next three years.
Total expected capex of approximately INR 1,000 crores for adding around 1,200-1,300 beds between FY24 and FY26.
INR 450 crores capex expected in the current year (FY24), including around INR 250 crores for the Noida Hospital project.
Noida facility: 550-bed hospital, expected to open in late FY25, operationalizing about 300 beds initially and scaling up as needed.
Gurgaon facility undergoing expansion with about 80 new senior doctors; adding ~30 beds in mother and child floor and ~50 beds for oncology daycare services through renovation.
Indore expansion via asset-light approach: partnering to build a 300-350 bed hospital; Medanta to equip and operate the facility.
Strong cash flows and net cash surplus of INR 4,692 million as of March 2023, well-positioned for funding future growth.

Track Global Health Ltd — get its next earnings analysis in your feed

How does Global Health Ltd rank vs peers in Healthcare Services?

Pro feature

ThisGlobal Health Ltd

Rev 2Mar 3

See where Global Health Ltd sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Global Health Ltd rank in Healthcare Services?

Compare Global Health Ltd against every Healthcare Services company (Q4 FY23) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Global Health Ltd's management said in earlier quarters

Others in Healthcare Services this season

Narayana Hrudayalaya Ltd (Q2 FY27)
Consolidated operating revenue for Q2 FY27: ₹28,440 Mn, up 73.0% YoY (Page 15, 16). Key investor presentation takeaways from Narayana Hrudayalaya Ltd's Q2 FY27
Artemis Medicare Services Ltd (Q2 FY27)
Q2 FY27 consolidated revenue from operations: INR 31,104 Lacs, up 13.2% YoY (Page 39, 40, 20). Key investor presentation takeaways from Artemis Medicare Service
Max Healthcare Institute Ltd (Q2 FY27)
Q2 FY27 Gross Revenue: ₹3,219 Cr, up 20% YoY (Page 4, 17) . Key investor presentation takeaways from Max Healthcare Institute Ltd's Q2 FY27 investor presentatio
Indegene Ltd (Q2 FY27)
Revenue from operations for Q2 FY27: INR 11,223 million, up 39.5% YoY (Page 23, 15, 4) . Key investor presentation takeaways from Indegene Ltd's Q2 FY27 investo

Compare:vs Apollo Hospitals Enterprise Ltd vs Manipal Health Enterprises Ltd vs Max Healthcare Institute Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →